MedTrace Logo

Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms

NCT00757978 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2008-12-18

No results posted yet for this study

Summary

Memantine as an add-on therapy to clozapine may improve schizophrenia negative symptoms and cognitive functioning.

Conditions

Interventions

DRUG

memantine

memantine 10mg twice a day

DRUG

placebo

1 capsule of placebo twice a day

Sponsors & Collaborators

  • Hospital de Clinicas de Porto Alegre

    lead OTHER

Principal Investigators

  • Clarissa S Gama, PhD · Hospital de Clinicas de Porto Alegre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-01-31
Completion
2008-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00757978 on ClinicalTrials.gov